Chee‐Keong Toh

5.6k total citations
71 papers, 1.8k citations indexed

About

Chee‐Keong Toh is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Chee‐Keong Toh has authored 71 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Pulmonary and Respiratory Medicine, 43 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Chee‐Keong Toh's work include Lung Cancer Treatments and Mutations (37 papers), Lung Cancer Diagnosis and Treatment (15 papers) and Lung Cancer Research Studies (15 papers). Chee‐Keong Toh is often cited by papers focused on Lung Cancer Treatments and Mutations (37 papers), Lung Cancer Diagnosis and Treatment (15 papers) and Lung Cancer Research Studies (15 papers). Chee‐Keong Toh collaborates with scholars based in Singapore, United States and Japan. Chee‐Keong Toh's co-authors include Wan‐Teck Lim, Eng-Huat Tan, Kam-Weng Fong, Balram Chowbay, Swan‐Swan Leong, Swan Swan Leong, Joseph Wee, Eng Huat Tan, Philip Eng and Heng‐Nung Koong and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Chee‐Keong Toh

69 papers receiving 1.8k citations

Peers

Chee‐Keong Toh

PRM

ONCOL

SURGE

Sang‐Hee Cho South Korea

Dean Lim United States

Dinesh Chandra Doval India

Nevena Damjanov United States

Luigi Manzione Italy

C. Couteau France

Jane Bryce Italy

Cristian Villanueva France

Desirée Hao Canada

Jin Hyoung Kang South Korea

Sang‐Hee Cho South Korea

Chee‐Keong Toh

496 ×0.5

PRM

639 ×0.7

ONCOL

470 ×1.0

182 ×0.8

510 ×2.2

SURGE

Citations per year, relative to Chee‐Keong Toh Chee‐Keong Toh (= 1×) peers Sang‐Hee Cho

Countries citing papers authored by Chee‐Keong Toh

Since Specialization

Citations

This map shows the geographic impact of Chee‐Keong Toh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chee‐Keong Toh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chee‐Keong Toh more than expected).

Fields of papers citing papers by Chee‐Keong Toh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chee‐Keong Toh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chee‐Keong Toh. The network helps show where Chee‐Keong Toh may publish in the future.

Co-authorship network of co-authors of Chee‐Keong Toh

This figure shows the co-authorship network connecting the top 25 collaborators of Chee‐Keong Toh. A scholar is included among the top collaborators of Chee‐Keong Toh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chee‐Keong Toh. Chee‐Keong Toh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Samol, Jens, Jonathan Poh, Min-Han Tan, et al.. (2025). Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK). JCO Precision Oncology. 9(9). e2500181–e2500181. 4 indexed citations

Ang, Mei‐Kim, Ekkasit Tharavichitkul, Cindy Lim, et al.. (2021). Phase II study of nimotuzumab (TheraCim‐hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. Head & Neck. 43(5). 1641–1651. 10 indexed citations

Toh, Chee‐Keong, et al.. (2020). Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer. Journal of Medical Economics. 23(9). 952–960. 16 indexed citations

Toh, Yi Long, Yi Pang, Maung Shwe, et al.. (2020). HPLC-MS/MS coupled with equilibrium dialysis method for quantification of free drug concentration of pazopanib in plasma. Heliyon. 6(4). e03813–e03813. 11 indexed citations

Tuan, Jeffrey, Kae Jack Tay, Ravindran Kanesvaran, et al.. (2019). ⁶⁸Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy. Cancer Biology and Medicine. 16(1). 157–157. 13 indexed citations

Tan, E.H., Wan‐Teck Lim, Mei‐Kim Ang, et al.. (2018). Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR mutations in Singapore. Annals of Oncology. 29. ix161–ix161. 5 indexed citations

Ng, Quan Sing, Cindy Lim, Eng Huat Tan, et al.. (2018). Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. BMC Cancer. 18(1). 1198–1198. 19 indexed citations

Gandhi, Mihir, Ru‐San Tan, Raymond Ng, et al.. (2017). Comparison of health state values derived from patients and individuals from the general population. Quality of Life Research. 26(12). 3353–3363. 13 indexed citations

Garassino, Marina Chiara, Naiyer A. Rizvi, Benjamin Besse, et al.. (2017). OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1–Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study. Journal of Thoracic Oncology. 12(1). S251–S252. 13 indexed citations

10.

Elgendy, Mohamed, Amal Kamal Abdel‐Aziz, Salvatore Lorenzo Renne, et al.. (2016). Dual modulation of MCL-1 and mTOR determines the response to sunitinib. Journal of Clinical Investigation. 127(1). 153–168. 50 indexed citations

11.

Tan, PH, et al.. (2016). Differential radiologic characteristics of renal tumours on multiphasic computed tomography. Singapore Medical Journal. 58(5). 262–266. 7 indexed citations

12.

Tan, Eng Huat, Daniel S.W. Tan, Benjamin Haaland, et al.. (2015). Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer. Lung Cancer. 88(3). 289–296. 17 indexed citations

13.

Chu, Ying‐Hsia, Huihua Li, Hui Shan Tan, et al.. (2015). Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. PLoS ONE. 10(8). e0134102–e0134102. 29 indexed citations

14.

Tan, Hui Shan, Huihua Li, Chee‐Keong Toh, et al.. (2014). Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore. Clinical Genitourinary Cancer. 13(4). e285–e295. 22 indexed citations

15.

Ngeow, Joanne, Wan‐Teck Lim, Swan Swan Leong, et al.. (2010). Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. Annals of Oncology. 22(3). 718–722. 53 indexed citations

16.

Choo, Su Pin, Wan‐Teck Lim, Chee‐Keong Toh, et al.. (2009). Gefitinib in Combination with Gemcitabine and Carboplatin in Never Smokers with Non-small Cell Lung Carcinoma: A Retrospective Analysis. Journal of Thoracic Oncology. 4(8). 988–993. 4 indexed citations

17.

Ngeow, Joanne & Chee‐Keong Toh. (2009). The Role of Pemetrexed Combined with Gemcitabine for Non-Small-Cell Lung Cancer. Current Drug Targets. 11(1). 61–66. 4 indexed citations

18.

Leong, Swan Swan, Chee‐Keong Toh, Wan‐Teck Lim, et al.. (2007). A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor Performance Status and/or Are Elderly. Journal of Thoracic Oncology. 2(3). 230–236. 34 indexed citations

19.

Toh, Chee‐Keong & Wan‐Teck Lim. (2006). Lung cancer in never-smokers. Journal of Clinical Pathology. 60(4). 337–340. 42 indexed citations

20.

Leong, Swan‐Swan, Joseph Wee, Miah Hiang Tay, et al.. (2004). Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma. Cancer. 103(3). 569–575. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact